

Ibrance (palbocicclib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:	
mportant for the review (dditional documentation that is quest). Information contained in
			☐ URGENT
MEMBER INFORMATION	N		
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:		1	
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID	NUMBER:	L	
F YOU ARE NOT THE PATIENT OR THE PE- FOLLOWING LINK: HTTPS://MAGELLAN	RESCRIBER, YOU WILL NEED TO SUBMIT A PHI I	EIGHT (LB/KG): ALLE DISCLOSURE AUTHORIZATION FORM WITH THIS COMMON/DOC/EN-US/PHI DISCLOSURE AU SLE):	REQUEST WHICH CAN BE FOUND AT THE THORIZATION.PDF
PRESCRIBER INFORMAT			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:		1	
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
MEDICATION OR MEDIC	CAL DISPENSING INFORMATION	ON	
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
■ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THER	APY INITIATED:
DURATION OF THERAPY	(SPECIFIC DATES):		

Continued on next page





Ibrance (palbocicclib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	IBER'S LAST NAME: MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2 LIST DIA CNOSES		100.40
2. LIST DIAGNOSES: Breast cancer		ICD-10:
⊔ Breast cancer		
3. REQUIRED CLINICAL INFORMATION	: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A
PRIOR AUTHORIZATION.		
Clinical Information:		
Is this drug being prescribed to this p trial? □ Yes □ No	atient as part of a treatment regimen	specified within a sponsored clinical
trial? Lifes Lino		
Does the nationt have estrogen recei	otor positive advanced breast cancer?	□ Ves □ No Please submit
documentation.	to positive advanced breast cancer.	a res alto rieuse suomie
Is the patient's breast cancer HER-2 r	egative? 🗆 Yes 🗆 No <i>Please submit</i> :	documentation.
	ent with fulvestrant? Yes No Do	cumentation of all previous treatment
regimens required.		
Use the metiont received prior treatme	ant with averalimus? Sves SNa Da	aumontation of all province treatment
regimens required.	ent with everolimus? Yes No Do	cumentation of all previous treatment
regimens required.		
Has the patient received prior treatm	ent with endocrine therapy? \Box Yes \Box	No Documentation of all previous
treatment regimens required.	• ,	, ,
Is the patient a postmenopausal fem	ale? □ Yes □ No	
Is the patient a pre/perimenopausal	female? 🗆 Yes 🗆 No	
Is the patient male? ☐ Yes ☐ No		
is the patient male: res No		
Will the patient use letrozole, anastra	azole or exemestine in combination wit	th Ibrance (palbociclib)?
Will the patient use fulvestrant in co	mbination with Ibrance (palbociclib)?	□ Yes □ No
	azole or exemestine in combination wi	th goserelin(Zoladex) and
Ibrance(palbociclib)? ☐ Yes ☐ No		
Renewal Requests:		
nenewal Reduests:		

 $\hbox{@ 2017-2023}$ by Magellan Rx Management. All Rights Reserved.

Revision Date: 4.15.24

CAT0111







Ibrance (palbocicclib) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Is patient continuing to demonstrate a positi	ive clinical response? Yes No Please submit documentation.
Are there any other comments, diagnoses, sy the physician feels is important to this review	ymptoms, medications tried or failed, and/or any other information y?
Please note: Not all drugs/diagnosis are covere information is received.	ed on all plans. This request may be denied unless all required
·	ed is true and accurate to the best of my knowledge. I understand that designees may perform a routine audit and request the medical f the information reported on this form.
Prescriber Signature or Electronic I.D. Verificat	tion: Date:
you are not the intended recipient, you are hereby notifie	g this transmission contain confidential health information that is legally privileged. If ed that any disclosure, copying, distribution, or action taken in re liance on the contents gived this information in error, please notify the sender immediately (via return FAX) ments.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program;

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

